Modalim (Ciprofibrate)

Ciprofibrate, the active ingredient in Modalim, is a fibrate presented as a oral tablet for oral use. It treats hypertriglyceridaemia and mixed dyslipidaemia in adult patients who require lipid‑modifying therapy.

GNH USA supplies Modalim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modalim, a fibrate, is used to manage disorders of elevated triglycerides and mixed lipid abnormalities. - Hypertriglyceridaemia: lowers markedly elevated triglyceride concentrations. - Mixed dyslipidaemia: reduces triglycerides while modestly increasing HDL‑cholesterol. - Secondary prevention of cardiovascular risk: improves overall lipid profile when added to diet and lifestyle measures.

Ciprofibrate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Elevated serum creatinine: transient rise in kidney function tests.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown requiring immediate medical attention. - Hepatotoxicity: significant elevation of liver enzymes or hepatitis. - Severe allergic reaction: rash, angioedema or anaphylaxis. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain and elevated enzymes.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients for potential risks. - Liver function monitoring: check ALT/AST before treatment and periodically thereafter. - Renal function assessment: evaluate serum creatinine and adjust use in renal impairment. - Concomitant statin therapy: avoid high‑dose statins to reduce myopathy risk. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Ciprofibrate can alter the pharmacokinetics or pharmacodynamics of several co‑administered drugs.

Major Interactions (Avoid): - Gemfibrozil: markedly increases risk of myopathy and rhabdomyolysis. - High‑dose statins (e.g., rosuvastatin): potentiate muscle toxicity. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Cyclosporine: can raise ciprofibrate plasma levels. - Cholestyramine: reduces ciprofibrate absorption, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Niacin: combined use may increase hepatotoxicity risk. - Digoxin: may require serum level checks due to altered clearance.